Categories Analysis, Industrials

What to expect when Southwest Airlines (LUV) reports Q2 2023 earnings

The company expects unit revenues for Q2 to be down 8-10% year-over-year

Shares of Southwest Airlines Co. (NYSE: LUV) were up 1% on Wednesday. The stock has gained 16% over the past three months. The airline company is set to report its second quarter 2023 earnings results on Thursday, July 27, before market open. Here’s a look at what to expect from the earnings report:


Analysts are projecting revenues of $6.9 billion for Southwest in Q2 2023. This would represent a growth of over 3% from the same period a year ago. In Q1 2023, operating revenues increased 22% year-over-year to $5.7 billion.


The consensus estimate is for earnings of $1.10 per share in Q2 2023, which compares to earnings of $1.30 per share reported in the year-ago quarter. In Q1, the company reported an adjusted loss per share of $0.27.

Points to note

Like its peers, Southwest is expected to benefit from strong travel demand. Leisure travel remains robust while managed business trends are expected to improve sequentially. The company expects unit revenues for Q2 to be down 8-10% year-over-year with capacity up around 14%.

Operating expenses per available seat mile, excluding fuel and oil expense, special items, and profitsharing, or CASM-X, is expected to be up 5-8% YoY in Q2. Economic fuel costs per gallon is estimated to be around $2.55.

Most Popular

Nike (NKE) looks set to beat hurdles and build a brighter future

Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business

Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company

Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as

Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications

Add Comment
Viewing Highlight